Nico Gagelmann: Role of molecular alterations in transplant decision for primary myelofibrosis
Nico Gagelmann , Co-chair of EBMT’s Trainee Committee, shared on X:
“Finally out.
Role of molecular alterations in transplant decision for primary myelofibrosis.
Wonderful international collaboration.”
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis
Authors: Damien Luque Paz, Nico Gagelmann, Lina Benajiba, Jérémie Riou, Rachel B Salit, Corentin Orvain, Thomas Schroeder, Claire Bories, Carmelo Gurnari, Anita Badbaran, Francoise Boyer-Perrard, Simona Pagliuca, Christina Rautenberg, Suzanne Tavitian, Victoria Panagiota, Jean-Christophe Ianotto, Felicitas R. Thol, Emilie Cayssials, Michael Heuser, Marie-Therese Rubio, Bruno Cassinat, Rafael Daltro de Oliveira, Craig S Sauter, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L Scott, Valérie Ugo, Nicolaus Kröger, Jean-Jacques Kiladjian, Marie Robin
More posts featuring Nico Gagelmann.
Nico Gagelmann is a physician and scientist who co-founded and co-chairs the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee, and he also serves as the chair of the EBMT subcommittee focused on CAR-T cell therapies for plasma cell disorders.
His work is particularly impactful in the realm of CAR-T treatments for multiple myeloma, where he has contributed to advancing research and clinical approaches.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023